Cancer · Austria
Acute myeloid leukaemia
How is it diagnosed today? Your family doctor usually arranges an urgent blood test, and may send you to a hospital specialist or straight to hospital. NHS
What do you need help with?
- Join a trialStudies open to new patients in your country, and abroad if you want.13 open trials in Austria
- Offer tissue or dataGive a sample or your health data to research.
- Get supportPatient groups, money and work, help for family.
- Access and costGetting a treatment that is not on offer here, and who pays.
- Questions for your doctorReady lists to print or copy before your next visit.
- Don't pay for thisOffers with no proof in people, and what to check first.
Where treatment stands
Four steps, from proven to unproven.
Approved in Austria
Usual treatment: Intensive chemo, sometimes a stem cell transplant. NHS
15 medicines are approved for this disease in Austria:
Show all 15
- Arsenic trioxide (Trisenox, Arsenic trioxide Accord, Arsenic trioxide medac) – approved in 2002
- Azacitidine (Onureg, Azacitidine Mylan, Azacitidine Kabi) – approved in 2008
- Cedazuridine and decitabine (Inaqovi, Inqovi) – approved in 2023
- Daunorubicin and cytarabine (Vyxeos liposomal, Vyxeos) – approved in 2018
- Decitabine (Dacogen, Decitabin Sandoz) – approved in 2012
- Gemtuzumab ozogamicin (Mylotarg) – approved in 2018
- Gilteritinib (Xospata) – approved in 2019
- Glasdegib (Daurismo) – approved in 2020
- Histamine dihydrochloride (Ceplene) – approved in 2008
- Ivosidenib (Tibsovo) – approved in 2023
- Melphalan (Phelinun) – approved in 2020
- Midostaurin (Rydapt) – approved in 2017
- Quizartinib (Vanflyta) – approved in 2023
- Venetoclax (Venclyxto, Venclexta) – approved in 2016
- Posaconazole (Noxafil, Posaconazole Accord, Posaconazole AHCL) – approved in 2005
An EU approval is valid in Austria. We did not check the national approvals in Austria, so some medicines under “Approved elsewhere” may be approved here too. We did not check whether they are sold or paid for there. Checked in the regulators' own texts on 11 Nov 2026.
Approved elsewhere (17)
- Cyclophosphamide (Frindovyx) – approved for it in the US
- Cytarabine (Cytarabine, Aracytine, Cytarabine Sandoz) – approved for it in the US and France
- Daunorubicin (Daunorubicin Hydrochloride, Daunoblastin, Cerubidine) – approved for it in the US, Switzerland, and France
- Doxorubicin (Doxorubicin Hydrochloride) – approved for it in the US
- Enasidenib (Idhifa) – approved for it in the US
- Etoposide (Celltop, Etopophos) – approved for it in France
- Filgrastim (Neupogen) – approved for it in the US
- Idarubicin (Zavedos, Idamycin PFS, Idarubicine Accord) – approved for it in the US and France
- Mercaptopurine (Purinethol) – approved for it in France
- Mitoxantrone (mitoXANTRONE) – approved for it in the US
- Olutasidenib (Rezlidhia) – approved for it in the US
- Revumenib (Revuforj) – approved for it in the US
- Sargramostim (Leukine) – approved for it in the US
- Thioguanine (Tabloid, Lanvis) – approved for it in the US and France
- Treosulfan (Grafapex) – approved for it in the US
- Tretinoin (Tretinoin, Vesanoid) – approved for it in the US, Switzerland, and France
- Ziftomenib (Komzifti) – approved for it in the US
Being tested in people
13 open trials in Austria, 635 worldwide. See the trials
- 4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine). (Phase 3)
- AG-120 (Phase 3)
- AG-221 (Phase 3)
- all-trans retinoic acid (ATRA) (Phase 3)
Only in the lab or in animals
Of the 20 newest articles, 2 were in animals and 1 in the lab. See them
No proof it works
Animal worm medicines (ivermectin, fenbendazole) for cancer: not approved, and not enough research in people to know if they help. American Cancer Society: What to Know About Ivermectin (21 May 2026) · American Cancer Society: What to Know About Fenbendazole (21 Oct 2025)
Join a trial
Studies that are taking new patients in Austria. The trial team decides who can join. Change the country at the top.
Phase 1: first tests in people · Phase 2: does it help? · Phase 3: compared with the usual treatment
8 open trials in Austria with these filters
Tests venetoclax with chemotherapy for newly diagnosed acute myeloid leukemia
NCT04628026 · ClinicalTrials.gov
- Innsbruck – Tirol Kliniken GmbH
- Linz – Kepler Universitaetsklinikum GmbH
- Linz – Ordensklinikum Linz GmbH
- and 3 more sites
Ages 18 to 75
Contact the trial teamTests bleximenib with chemotherapy in newly diagnosed acute myeloid leukemia
NCT07223814 · ClinicalTrials.gov
- Linz – Ordensklinikum Linz GmbH
- Vienna – Hanusch Krankenhaus der Wiener Gebietskrankenkasse
Age 18 and over
Contact the trial teamTests bleximenib with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia
NCT06852222 · ClinicalTrials.gov
- Linz – Ordensklinikum Linz GmbH Elisabethinen
- Linz – Kepler Universitatsklinikum GmbH
- Salzburg – Universitaetsklinikum Salzburg Landeskrankenhaus
- and 3 more sites
Age 18 and over
Contact the trial teamPivekimab sunirine added to venetoclax and azacitidine for newly diagnosed acute myeloid leukemia
NCT07581002 · ClinicalTrials.gov
- Graz – Medical University of Graz
- Linz – Ordensklinikum Linz GmbH
- Vienna – Medical University of Vienna
- and 1 more site
Age 18 and over
Contact the trial teamTests revumenib with chemotherapy for newly diagnosed acute myeloid leukemia with NPM1 mutation
NCT07211958 · ClinicalTrials.gov
- Graz – Medical University of Graz
- Innsbruck – Medizinische Universitaet Innsbruck
- Linz – Ordensklinikum Linz GmbH
- and 1 more site
Age 12 and over
Contact the trial teamAdding revumenib to standard treatment for newly diagnosed acute myeloid leukemia
NCT06652438 · ClinicalTrials.gov
- Linz – Kepler Universitaetsklinikum GmbH
- Salzburg – SCRI CCCIT Ges.m.b.H.
- Vienna – Hanusch Krankenhaus der Wiener Gebietskrankenkasse
Age 18 and over
Contact the trial teamTests ivosidenib with azacitidine in adults with a leukemia gene mutation
NCT05907057 · ClinicalTrials.gov
- Linz – Ordensklinikum Linz GmbH
- Vienna – Medical University of Vienna
- Wels – Klinikum Wels-Grieskirchen GmbH
Age 18 and over
Contact the trial teamAdding venetoclax to standard treatment for IDH1-mutated acute myeloid leukemia
NCT07075016 · ClinicalTrials.gov
- Feldkirch – AT-Feldkirch-IKHF
- Salzburg – AT-Salzburg-SALK
- Vienna – AT-Vienna-HANUSCH
Age 18 and over
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial team
Available abroad (117 trials)
Nearest region first. Travel and treatment abroad are often not paid for; ask your health insurer first.
Tests oral decitabine with ivosidenib in older adults with acute myeloid leukemia
NCT07507760 · ClinicalTrials.gov
Countries: Spain, Portugal
- Albacete, Spain – Complejo Hospitalario de Albacete
- Alcalá de Henares, Spain – Hospital Principe de Asturias
- Alicante, Spain – Hospital General Universitario Dr. Balmis
Age 18 and over
Contact the trial teamAdding quizartinib to venetoclax and azacitidine for older adults with acute myeloid leukemia
NCT07478991 · ClinicalTrials.gov
Countries: Spain
- Albacete, Spain – Complejo Hospitalario de Albacete
- Alcalá de Henares, Spain – Hospital Principe de Asturias
- Alicante, Spain – Hospital General Universitario Dr. Balmis
Age 18 and over
Contact the trial teamTests ziftomenib with standard drugs for untreated AML with certain gene changes
NCT07007312 · ClinicalTrials.gov
Countries: Belgium, Czechia, Germany and 14 more
- Jette, Belgium – UZ Brussel
- Liège, Belgium – Centre Hospitalier Universitaire de Liège
- Roeselare, Belgium – Algemeen Ziekenhuis Delta
Age 18 and over
Contact the trial teamTesting QTX-2101 with ATRA in adults newly diagnosed with acute promyelocytic leukemia
NCT07504458 · ClinicalTrials.gov
Countries: Spain, France, Italy and 2 more
- Badalona, Spain – Institut Catala d'Oncologia (ICO) Badalona - Hospital Universitari Germans Trias i Pujol
- Barcelona, Spain – Hospital de la Santa Creu i Sant Pau
- Barcelona, Spain – Hospital Universitari Vall d'Hebron
Ages 18 to 71
Contact the trial teamAdding quizartinib to venetoclax and azacitidine for newly diagnosed acute myeloid leukemia
2025-522979-29-00 · EU Clinical Trials Register
Countries: Spain
- A Coruña, Spain – Complexo Hospitalario Universitario A Coruña
- Albacete, Spain – Hospital General Universitario de Albacete
- Alcalá de Henares, Spain – Hospital Universitario Principe de Asturias
Age 18 and over
Contact the trial teamTests eganelisib alone and with other drugs in blood cancers
NCT06533761 · ClinicalTrials.gov
Countries: Spain, United States
- Cáceres, Spain – Hospital San Pedro De Alcántara
- Valencia, Spain – Hospital Universitario Y Politecnico La Fe
- Aurora, United States – Anshutz Cancer Pavilion
Age 18 and over
Contact the trial teamComparing two treatment intensities after leukemia or lymphoma shows no remaining disease
2024-512503-39-00 · EU Clinical Trials Register
Countries: Germany, France, Italy and 1 more
- Augsburg, Germany – Universitaetsklinikum Augsburg
- Berlin, Germany – Charite Universitaetsmedizin Berlin KöR
- Chemnitz, Germany – Klinikum Chemnitz gGmbH
Age 18 and over
Contact the trial teamTests cobicistat-boosted venetoclax with azacitidine in adults with newly diagnosed AML
NCT06014489 · ClinicalTrials.gov
Countries: Netherlands
- Amersfoort, Netherlands – Meander Medisch Centrum
- Amsterdam, Netherlands – Amsterdam UMC
- Arnhem, Netherlands – Rijnstate Ziekenhuis Stichting
Age 18 and over
Contact the trial teamOral decitabine plus ivosidenib for newly diagnosed acute myeloid leukemia in older adults
2025-523238-17-00 · EU Clinical Trials Register
Countries: Spain, Portugal
- Albacete, Spain – Hospital General Universitario de Albacete
- Alcalá de Henares, Spain – Hospital Universitario Principe de Asturias
- Alicante, Spain – Hospital General Universitario Dr. Balmis
Age 18 and over
Contact the trial teamIPN60340 added to azacitidine and venetoclax for newly diagnosed acute myeloid leukemia
NCT07623187 · ClinicalTrials.gov
Countries: Germany, France
- Berlin, Germany – Charite Universitaetsmedizin Berlin KöR
- Cologne, Germany – Universitaetsklinikum Koeln AöR
- Dresden, Germany – Technische Universitaet Dresden
Age 18 and over
Contact the trial teamVenetoclax and azacitidine compared with standard chemotherapy in newly diagnosed leukemia
NCT05904106 · ClinicalTrials.gov
Countries: Germany
- Aachen, Germany – Universitaetsklinikum Aachen AöR
- Augsburg, Germany – Universitaetsklinikum Augsburg
- Bamberg, Germany – Sozialstiftung Bamberg
Ages 18 to 70
Contact the trial teamAdding tambiciclib to venetoclax and azacitidine for acute myeloid leukemia that did not respond
2025-524308-31-00 · EU Clinical Trials Register
Countries: Spain, Italy
- Albacete, Spain – Hospital General Universitario de Albacete
- Alicante, Spain – Hospital General Universitario Dr. Balmis
- Valencia, Spain – Consorcio Hospital General Universitario de Valencia
Age 18 and over
Contact the trial teamCPX-351 Compared With Standard Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia
NCT05260528 · ClinicalTrials.gov
Countries: France
- Amiens, France – Centre Hospitalier Universitaire Amiens - Picardie
- Angers, France – Centre Hospitalier Universitaire D'Angers
- Avignon, France – Centre Hospitalier d'Avignon
Age 18 and over
Contact the trial teamTests lisaftoclax with azacitidine for newly diagnosed acute myeloid leukemia
NCT06389292 · ClinicalTrials.gov
Countries: Spain, Italy, Poland and 2 more
- Badalona, Spain – Institut Catala d'Oncologia
- Palma, Spain – University Hospital Son Espases
- Lecce, Italy – Ospedale Vito Fazzi Lecce
Age 18 and over
Contact the trial teamTests midostaurin and gemtuzumab with chemotherapy for newly diagnosed acute myeloid leukemia
NCT04385290 · ClinicalTrials.gov
Countries: Germany
- Aachen, Germany – Universitaetsklinikum Aachen AöR
- Augsburg, Germany – Universitaetsklinikum Augsburg
- Chemnitz, Germany – Klinikum Chemnitz gGmbH
Ages 18 to 75
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial teamTesting new treatment combinations for children with newly diagnosed acute myeloid leukemia
NCT05994690 · ClinicalTrials.gov
Countries: Netherlands
- Utrecht, Netherlands – Princess Máxima Center for Pediatric Oncology
Ages 0 to 18
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial teamTests quizartinib with chemotherapy in children with newly diagnosed leukemia
NCT06262438 · ClinicalTrials.gov
Countries: Belgium, Denmark, Estonia and 7 more
- Brussels, Belgium – Association Hospitaliere De Bruxelles Hopital Universitaire Des Enfants Reine Fabiola
- Leuven, Belgium – UZ Leuven
- Liège, Belgium – CHC MontLégia
Ages 0 to 18
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial teamTests shorter venetoclax dosing with azacitidine in acute myeloid leukemia
NCT07082452 · ClinicalTrials.gov
Countries: Spain, France
- Albacete, Spain – Hospital General Universitario de Albacete
- Alicante, Spain – Hospital General Universitario Dr. Balmis
- Cáceres, Spain – Hospital San Pedro De Alcántara
Age 70 and over
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial teamTests gilteritinib with chemotherapy in adults with newly diagnosed FLT3-positive acute myeloid leukemia
NCT06667973 · ClinicalTrials.gov
Countries: Italy
- Ancona, Italy – Azienda Ospedaliero-Universitaria delle Marche
- Bari, Italy – Istituto Tumori Bari Giovanni Paolo II
- Bergamo, Italy – Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
Ages 18 to 65
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial teamTests gemtuzumab with chemotherapy in adults with newly diagnosed acute myeloid leukemia
NCT04168502 · ClinicalTrials.gov
Countries: Italy
- Ancona, Italy – Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I G M Lancisi G Salesi
- Ascoli Piceno, Italy – Azienda Sanitaria Territoriale di Ascoli Piceno
- Avellino, Italy – AORN San Giuseppe Moscati Avellino
Ages 18 to 60
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial teamSulfasalazine added to standard chemotherapy for older adults with newly diagnosed leukemia
NCT05580861 · ClinicalTrials.gov
Countries: France
- Amiens, France – CHU Amiens
- Bobigny, France – Hopital Avicenne
- Caen, France – CHU Caen
Age 60 and over
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial teamTesting Enasidenib with Venetoclax and ASTX727 in Newly Diagnosed Acute Myeloid Leukemia
NCT06672146 · ClinicalTrials.gov
Countries: Puerto Rico, United States
- San Juan, Puerto Rico – San Juan City Hospital
- San Juan, Puerto Rico – Centro Comprensivo de Cancer de UPR
- Albuquerque, United States – University of New Mexico Cancer Center
Age 18 and over
Contact the trial teamCompares mesutoclax with venetoclax, both plus azacitidine, in untreated acute myeloid leukemia
NCT07925190 · ClinicalTrials.gov
Countries: China
- Hangzhou, China – The First Affiliated Hospital Zhejiang University School of Medicine
Age 18 and over
Contact the trial teamAn All-Oral Combination of Ivosidenib, Sonrotoclax, and Chidamide for Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation (ISC)
NCT07937124 · ClinicalTrials.gov
Age 18 and over
Contact the trial teamDrug combinations for newly diagnosed acute promyelocytic leukemia
NCT01409161 · ClinicalTrials.gov
Countries: United States
- Houston, United States – MD Anderson Regional Care Center-Katy
- Houston, United States – M D Anderson Cancer Center
- Nassau Bay, United States – MD Anderson Regional Care Center-Bay Area
Age 10 and over
Contact the trial teamTesting New Treatment Combinations for Newly Diagnosed High-Risk Acute Myeloid Leukemia
NCT05554406 · ClinicalTrials.gov
Countries: Canada, Puerto Rico, United States
- Calgary, Canada – Arthur J.E. Child Comprehensive Cancer Centre
- Edmonton, Canada – University of Alberta Hospital
- Greenfield Park, Canada – CSSS Champlain-Charles Le Moyne
Ages 18 to 59
Contact the trial teamShorter versus standard venetoclax with ASTX727 for older adults with newly diagnosed AML
NCT07437950 · ClinicalTrials.gov
Countries: Puerto Rico, United States
- San Juan, Puerto Rico – Centro Comprensivo de Cancer de UPR
- San Juan, Puerto Rico – San Juan City Hospital
- Anaconda, United States – Community Hospital of Anaconda
Age 60 and over
Contact the trial teamRevumenib with azacitidine and venetoclax for newly diagnosed KMT2A-rearranged acute myeloid leukemia
NCT07605949 · ClinicalTrials.gov
Countries: United States
- Chapel Hill, United States – Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill
Ages 18 to 65
Contact the trial teamVenetoclax with chemotherapy for acute myeloid leukemia
NCT03214562 · ClinicalTrials.gov
Countries: United States
- Houston, United States – M D Anderson Cancer Center
Age 18 and over
Contact the trial teamTests bortezomib with CPX-351 in adults with newly diagnosed TP53-mutated acute myeloid leukemia
NCT07008638 · ClinicalTrials.gov
Countries: United States
- Minneapolis, United States – Masonic Cancer Center
Age 18 and over
Contact the trial teamTests venetoclax with chemotherapy in newly diagnosed acute myeloid leukemia
NCT07228273 · ClinicalTrials.gov
Countries: United States
- Portland, United States – OHSU Knight Cancer Institute
Ages 18 to 65
Contact the trial teamImaging scans to find leukemia spread outside the bone marrow
NCT02390635 · ClinicalTrials.gov
Countries: United States
- Houston, United States – M D Anderson Cancer Center
Age 18 and over
Contact the trial teamVenetoclax Treatment with Donor Cell Infusion for New Acute Myeloid Leukemia
NCT07078591 · ClinicalTrials.gov
Countries: China
- Beijing, China – Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital
Age 18 and over
Contact the trial teamChemotherapy and Antibody Treatment for Newly Diagnosed Acute Myeloid Leukemia
NCT00801489 · ClinicalTrials.gov
Countries: United States
- Houston, United States – M D Anderson Cancer Center
Age 18 and over
Contact the trial teamTests venetoclax with chemotherapy drugs in untreated acute myeloid leukemia
NCT03586609 · ClinicalTrials.gov
Countries: United States
- Houston, United States – M D Anderson Cancer Center
Age 50 and over
Contact the trial teamMeasures physical age and health in older adults with newly diagnosed AML
NCT05909501 · ClinicalTrials.gov
Countries: United States
- Philadelphia, United States – Abramson Cancer Center at University of Pennsylvania
Age 50 and over
Contact the trial teamHeart Effects of Two Treatment Approaches in Newly Diagnosed Acute Myeloid Leukemia
NCT07851012 · ClinicalTrials.gov
Age 16 and over
Contact the trial teamTesting two cancer drugs together in adults with acute myeloid leukemia
NCT03629171 · ClinicalTrials.gov
Countries: United States
- Houston, United States – M D Anderson Cancer Center
Age 18 and over
Contact the trial teamLiposomal mitoxantrone added to azacitidine and venetoclax for new AML
NCT07828535 · ClinicalTrials.gov
Ages 18 to 99
Contact the trial teamCompares standard chemotherapy with CPX-351 and gilteritinib in newly diagnosed leukemia
NCT04293562 · ClinicalTrials.gov
Countries: Australia, Canada, Puerto Rico and 1 more
- Perth, Australia – Perth Children's Hospital
- Randwick, Australia – Sydney Children's Hospital
- South Brisbane, Australia – Queensland Children's Hospital
Ages 0 to 21
Contact the trial team
Showing 40 of 117. Use the filters to narrow the list.
How to get into an early trial
- A lab does not treat patients, so you cannot phone the lab to get a new treatment.
- Ask your doctor to look at phase 1 trials with you. These are the first tests in people.
- If one fits, your doctor sends a referral to the trial centre.
- The trial team checks whether you can join and decides.
Trial data: ClinicalTrials.gov, courtesy of the U.S. National Library of Medicine; it does not endorse this site. EU trials: EU Clinical Trials Information System (CTIS), European Medicines Agency. We show the registry records; the trial team has the last word on who can join.
Latest research
The five newest articles. The label comes from the PubMed index: whether it was tested in people, in animals or only in the lab.
- Higher Relapse Rate and Resource Utilization With Ara-C Consolidation Chemotherapy Alone Compared to Hematopoietic Cell Transplantation in First Remission in a Cohort of Younger Adults With Acute Myeloid Leukemia With t(8;21) (q22;q22.1).J Hematol · 2026-10-31
- In animalsAll-Trans Retinoic Acid-Loaded Fe-N3-Se Single-Atom Nanozymes Enable Redox-Guided Differentiation Therapy for Acute Myeloid Leukemia.ACS Nano · 2026-11-17
- In animalsIntravital Microscopy-Guided Live-Cell Isolation for Spatially Resolved Transcriptional Analysis of Leukemia-Immune Interactions.J Vis Exp · 2026-11-10
- Impact of Molecular and Cytogenetic Risk Stratification, Early Treatment Response, and Inflammatory Biomarkers on Survival in Intensively Treated Non-Acute Promyelocytic Leukemia Acute Myeloid Leukemia.World J Oncol · 2026-11-11
- In peopleEarly bone marrow-guided venetoclax management in frontline unfit acute myeloid leukemia: a two-stage real-world study.Ann Hematol · 2026-08-20
Is it true?
Saw something on social media? Fact-check it now.
Get screened
For family members and people at higher risk: free checks can find some cancers early, before there are symptoms.
There is no routine screening for this cancer. If you have symptoms or a family history, talk to your doctor.
If several people in your family had cancer, ask your GP whether genetic counselling makes sense for you.
Offer tissue or data
You can help research move faster.
Give tissue or blood to research
Before an operation or a blood test, ask if left-over tissue or blood can go to a biobank.
- Does this hospital have a biobank?
- What will the sample be used for, and for how long?
- Can I change my mind later?
Share your health data
Ask your doctor whether there is a patient registry for your illness. You choose what you share.
Take part as a healthy volunteer
Some studies need people without the illness, often family members.
Volunteer studiesGet support
Patient groups in Austria
- Österreichische Krebshilfe
Free, anonymous counselling at regional centres in every federal state, psycho-oncology and emergency financial aid.
Phone: 01 7966450
Help for every illness in Austria (4)
- 1450 – Rund-um-die-Uhr-Gesundheitsberatung
Austria's nationwide 24/7 telephone health advice line: trained staff assess symptoms and guide callers to the appropriate care.
- Telefonseelsorge Österreich – Notruf 142
Free, confidential 24/7 emotional support and crisis line for anyone in Austria, reachable on 142.
- Gesundheitsportal Österreich (gesundheit.gv.at)
Austria's official public health portal, offering quality-assured information on diseases, prevention, health services and patient rights.
- ARGE Selbsthilfe Österreich
ARGE Selbsthilfe Österreich represents the interests of self-help groups and patient organisations in Austrian social and health policy.
Available abroad: international groups (8)
- DKMS
Finds blood stem cell donors worldwide so that people with blood cancer can have a transplant.
- Acute Leukemia Advocates Network (ALAN)
Global network of 69 acute leukaemia patient organisations (hosted by the Swiss Leukemia Patient Advocates Foundation); member list helps patients find a national group.
- European Cancer Patient Coalition (ECPC)
Umbrella of European cancer patient groups, with a patient toolbox and a legal network for cancer patients.
- European Reference Networks (European Commission)
The European Commission's 24 expert networks for rare and complex diseases; your doctor can contact them.
- EURORDIS – Rare Diseases Europe
Alliance of over 1,000 rare disease patient organisations, with a list of rare disease helplines by country.
- Workgroup of European Cancer Patient Advocacy Networks
Network of pan-European cancer patient umbrella groups (including the blood cancer networks): joint advocacy, WECAN Academy training for patient advocates, patient experience data courses.
- European Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
- International Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Money and work
If the illness stops you working, ask the hospital social worker which benefits you can claim.
- Which sick-pay or disability benefits can I apply for?
- Is there help for the carer in the family?
- Are travel costs to treatment paid back?
After a loss
If someone you love has died, you do not have to go through it alone. Many families ask themselves whether they missed something; the care team can talk this through with you.
We have no grief support group in Austria in our list yet. The hospital's social worker or palliative team can tell you where to find one.
Hospitals and hospices have chaplains and counsellors, for any faith or none.
Some families decide to give tissue to research after death, so that the illness can be studied. If you want to, ask the treating hospital early whether it has such a programme.
Access and cost
- If no trial fits, your doctor can ask the company and the medicines authority whether early access (compassionate use) is possible.
- In Austria the medicines agency BASG lists the early-access programmes that are running. BASG (Austria): list of compassionate use programmes, no. 054
- In the EU you may get planned care in another EU country. Ask your health insurer before you go. Your Europe: planned medical treatment abroad
- Some medicines for this disease are approved abroad but maybe not here: see “Approved elsewhere” under “Approved in Austria” above.
Don't pay for this
No one will cure you through a Facebook message or ask you to invest money.
- Animal worm medicines bought online (ivermectin, fenbendazole)
They are made for animals and not tested for cancer in people. High doses can cause seizures or coma, fenbendazole has caused liver damage, they may weaken your cancer treatment, and they can keep you out of a trial.
American Cancer Society: What to Know About Ivermectin (21 May 2026) · American Cancer Society: What to Know About Fenbendazole (21 Oct 2025) · ASCO: Oncologists urged to discuss ivermectin and fenbendazole (17 Jun 2026)
- “Treatment plans” offered in comments
Ask which published study in people is behind it. Usually there is none.
- Anyone who answers your post with a private treatment
Real trials are listed in a public registry. Check the number on ClinicalTrials.gov or the EU trial register.
- Strangers offering investments or “funds” for treatment
Do not reply and do not send money. Report the comment or message.
Before you pay for anything, ask three things
- Can I have a written price, with everything that is included?
- Which published study in people shows it helps my disease?
- What does my doctor say about it?
Questions for your doctor
Ready lists for a new diagnosis, during treatment, before a trial and before you pay. Open the question lists
Not medical advice. We show what is open and what is known; your care team decides what fits you.